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ABSTRACT 
Objective: The present work was executed to evaluate the antidiabetic potency of herbal preparation which was the combination of 
wheat germ oil, fresh juice of Coriander sativum and Aloe vera gel in normal and alloxan-induced diabetic mice.  
Methods: The serum glucose lowering activity of the herbal preparation (PH-1 in the ratio of 1:1:1of wheat germ oil, fresh juice of 
C. sativum and Aloe vera) was studied in normal rats after oral administration at 1.0 and 2.0 ml/kg and herbal preparation (PH-1, 
PH-2 wheat germ oil, fresh juice of coriander sativum and Aloe vera gel in ratio of 2:2:1) and PH-3 (wheat germ oil, fresh juice of 
coriander sativum and Aloe vera gel in ratio of 1:2:2) on alloxan induced diabetic swiss albino mice, at doses of 1.0 and 2.0 ml/kg. 
Blood samples were collected and analyzed for serum glucose at 0,1/2, 1, 2, 4, 8, 12 and 24 h in normal mice and at 0, 1, 3, 7, 15 and 
30 days in diabetic mice after drug administration by glucose oxidase/peroxidase method. The data were compared statistically by 
using one way ANOVA method followed by Dunnett multiple component test. Statical significance was set at p<0.05.  
Results: The herbal preparation (1.0 and 2.0 ml/kg) produced significant (p<0.05) reduction in serum glucose level of both normal 
and diabetic mice and comparable with that of control and standard drug Glibenclamide. 
Conclusion: The herbal preparation showed significant glucose lowering effect in normal and alloxan induced diabetic rats. This 
preparation is giving to be a promising antidiabetic preparation for masses and however, it requires further extensive studies in 
human beings.  
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INTRODUCTION 
An inactive life, which involves lack of exercise & poor 
calorie management, is one of the biggest contributors to 
the dreaded disease of diabetes
1
. India is facing an 
epidemic of diabetes. At present confirmed diabetes 
patients in India are 62 million, with another 30 million 
pre-diabetes group. By 2030, diabetes mellitus may 
afflict up to 79.4 million individuals in India
2
. Diabetes 
is not only a blood sugar problem, but brings along other 
complications as well. Diabetes can be treated by 
chemicals or drugs e.g. Pramlintide such as (SymlinPen 
120, SymlinPen 60). But these drugs have various side 
effects also such as nausea
3
, vomiting, and watery 
diarrhea, headache and indigestion, mild allergic 
reactions with rash, itchiness and fever, problems with 
the kidneys, liver, lungs and pancreas. But due to their 
various side effects and consumer awareness, people are 
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moving towards natural and safe means for treating the 
diseases. 
Diabetes mellitus is one of the disease for which a 
satisfactory treatment is not available in modern 
allopathic system of medicine
4
. Therefore the search for 
an ideal drug for the treatment of diabetes containing 
and has been extended to herbs
5
. Antidiabetic drug from 
natural sources is preferred because of their less toxicity 
and a negligible side effect on to the body
6
, 
7
.     
On perusal of literature survey, we found that the 
indigenous Indian system of medicine (Ayurveda) a 
mention was made on the good number of plants for the 
cure of diabetes, but the bio reactivity of single plant 
preparation is disappointing whereas combination of 
substance are likely to contain several bio reactive 
components which act together and elicit additive and 
synergistic effects which shows optimal therapeutic 
response that are not apparent when the single plant 
preparation are used. Therefore, we have selected three 
different plants product in our study, namely wheat germ 
oil, fresh juice of coriander sativum and Aloe vera. Aloe 
vera has been reported to have hypoglycemic activity. 
Hence, the specific objectives aimed in the present work 
are as follows: 
 To ascertain the effectiveness of Polyherbal 
preparation for hypoglycemic activity in normal 
mice.                                                
 To explore the effect of Polyherbal preparation 
for anti-diabetic activityin diabetic mice.                              
MATERIALS AND METHODS 
A. Materials                                                           
The Polyherbal preparation which was used in the 
study has been prepared by using Wheat germ oil 
which has been provided by Bhaiji Attarwali 
perfumers (P) Ltd. Delhi,  
Aloe vera gel collected from Aloe vera leaf which has 
been provided by Sree Siddaganga College of 
pharmacy botanical garden, Tumku rand fresh juice 
of Coriander leaves collected from Tumkur district 
and were authenticated by Prof. K. Siddappa, Head, 
Department of Botany, Sree Siddaganga Boy’s 
College, Tumkur. Aloe vera leaves were washed 
properly to remove their. After washing, remove the 
skin of leaves, gels were separated and collected. Fresh 
juice of C. sativum obtained by crushing leaves in 
mortar and squeezed the crushed material by means of 
fine cloth to separate the juice and collected the fresh 
juice of leaves. Alloxan, sodium chloride, and acacia 
were obtained from S.D. Fine-Chem Limited, 
Mumbai. Glibenclamide tablet (5mg) was obtained 
from Nichols piramal India limited. Glucose estimation 
kit was supplied by Qualigens diagnostics. 
 
B. Development of Animal model for diabetes 
mellitus: 
1 .  Animals  
For pharmacological experiments, swiss albino mice 
(28-32g) of either sex were used. The animals were 
obtained from animal house of Sree Siddaganga College 
of Pharmacy, Tumkur [Ref: 123/1999/CPCSEA dated 
19/5/99]. Protocol of the experiments and animal usage 
were discussed in the Institutional Ethical Committee 
meeting and permission has been obtained to carry out 
the parameters selected for the study (See annexure-II) 
[Ref: SSCPT/ IAEC. Clear/ 41/ 2006-07 dated 
25/11/06]. 
2. Housing of Animal 
Animals were maintained in suitable nutritional and 
environmental condition throughout the experiment. 
They were provided with food, water ad libitum. The 
bedding material of the cages was changed every day. 
The animals were maintained under natural day and 
night cycle. 
3. Preparation of control and Test formulations.  
 Preparation of alloxan monohydrate 5% solution
8 
 
Alloxan monohydrate, 250 mg was dissolved in 5.0 ml 
of 0.9% sodium chloride to give 5.0% of Alloxan 
solution and injected immediately through the ip route 
within 5 min to avoid degradation. 
Glibenclamide Solution
9
: 
Glibenclamide tablet of 5 mg was dissolved in 83.33 ml 
of distilled water to give 60 g/ml solution. This 
solution was administered at a dose of 600 g/ kg body 
weight using clean and dry oral feeding needle for 30 
days. 
Preparation of herbal preparation (PH1, PH2 and 
PH3): 
Herbal preparation-I (PH1): It consists of Wheat germ 
oil, fresh juice of Coriandrum sativum and Aloe vera in 
the ratio of 1:1:1. Formulation was prepared by using 
acacia as a binding agent. 
Take 2.0 ml of wheat germ oil. Transfer it into a dry 
mortar. Add 500 mg of gum acacia powder, mixed 
thoroughly by trituration. Add 1.0 ml of Coriander juice 
at the time of continuous trituration until a light green 
product with clicking sound is produced. Primary 
emulsion was formed. Add Aloe vera gel 2.0 ml with 
remaining 1.0 ml of coriander juice separately. Add this 
solution at a time to primary emulsion with continuous 
and rapid trituration. The emulsion was used for study. 
Herbal preparation-II (PH2): It consists of Wheat 
germ oil, fresh juice of Coriandrum sativum and Aloe 
vera in the ratio of 2:2:1. Formulation was prepared by 
using acacia as a binding agent. 
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Take 2.0 ml of wheat germ oil. Transfer it into a dry 
mortar. Add 500 mg of gum acacia powder, mixed 
thoroughly by trituration. Add 1.0 ml of Coriander juice 
at the time of continuous trituration until a light green 
product with clicking sound is produced. Primary 
emulsion was formed. Add Aloe vera gel 1.0 ml with 
remaining 1.0 ml of coriander juice separately. Add this 
solution at a time to primary emulsion with continuous 
and rapid trituration. The emulsion was used for study. 
Herbal preparation-III (PH3): It consists of Wheat 
germ oil, fresh juice of Coriandrum sativum and Aloe 
vera in the ratio of 1:2:2. Formulation was prepared by 
using acacia as a binding agent. 
Take 1.0 ml of wheat germ oil. Transfer it into a dry 
mortar. Add 250 mg of gum acacia powder, mixed 
thoroughly by trituration. Add 1.0 ml of Coriander juice 
at the time of continuous trituration until a light green 
product with clicking sound is produced. Primary 
emulsion was formed. Add Aloe vera gel 2.0 ml with 
remaining 1.0 ml of coriander juice separately. Add this 
solution at a time to primary emulsion with continuous 
and rapid trituration. The emulsion was used for study. 
C. Pharmacological evaluation 
Experimental Animals: 
For pharmacological experiments, swiss albino mice 
(28-32g) of either sex were used. 
Induction of hyperglycemia with alloxan
8, 10
: 
Swiss albino mice (28–32 g) were fasted for 14 h before 
challenging with single injection (i.p) of Alloxan 
monohydrate 5.0%, freshly prepared and injected within 
5 min of preparation to prevent degradation at a dose of 
150 mg/kg, i.p. After administration of alloxan the 
animals had free access to feed and water ad libidum. 
The blood glucose was measured 72 h of alloxanisation. 
After one week when the condition of diabetes was 
stabilized, the animals were fasted again for 14 h before 
blood collection withdrawal from retro orbital plexus. 
The swiss albino mice with fasting serum glucose level 
of above 200 mg/dl were considered diabetic and 
included in the study. 
Experimental design: 
The experimental setup consist of twelve groups, each 
group consist of five animals. 
Group-I: Vehicle control received saline solution (0.9% 
NaCl). 
Group-II: Normal mice received Glibenclamide as 
standard, single dose. 
                  (Dose: 600 μg/kg). 
Group-III: Normal mice received PH-1, single dose.  
                   (Dose: 1.0 ml/kg). 
Group-IV: Normal mice received PH-1, single dose. 
                  (Dose: 2.0 ml/kg). 
Group-V: Alloxan induced mice received saline solution 
(0.9% NaCl). 
Group-VI: Diabetic mice given Glibenclamide as standard, 
orally once daily.  
                    (Dose: 600 μg/kg). 
Group-VII: Diabetic mice given PH-1, orally once daily. 
                     (Dose: 1.0 ml/kg). 
Group-VIII: Diabetic mice given PH-1, orally once daily.  
                      (Dose: 2.0 ml/kg). 
Group-IX: Diabetic mice given PH-2, orally once daily.  
                   (Dose: 1.0 ml/kg). 
Group-X: Diabetic mice given PH-2, orally once daily.  
                  (Dose: 2.0 ml/kg). 
Group-XI: Diabetic rats given PH-3, orally once daily. 
                  (Dose: 1.0 ml/kg). 
Group-XII: Diabetic rats given PH-3, orally once daily. 
                    (Dose: 2.0 ml/kg). 
Care of Diabetic Animals: 
Since diabetic animals drink large amount of fluid and 
produce large volume of urine, the bedding is changed 
frequently, usually every day, and, in some 
circumstances, more than once per day. Diabetic rats 
should have sufficient food and water; therefore only 
three diabetic mice have been housed per cage to avoid 
competition for feed and water. 
Blood sampling and blood glucose determination
9
: 
The swiss albino mice were placed on the working table, 
a mortar was inverted on it, and no gap was maintained 
in between mortar and the edge of the working platform. 
The tail was pulled out from the mortar’s beak gap and 
the tail was depilated. The tail was cleaned with spirit 
and allowed to dry; tail vein was dilated by focusing a 
low voltage electric lamp at the tip of tail for few 
seconds. After the dilation of the vein the blood was 
drawn by tail vein method from mice (fasted for 14 h) on 
different occasion, i.e., at 0, 0.5, 1, 2, 4, 8, 12, and 24 h 
after oral administration of drug in groups I to IV, 
Where as in group V to XII at 0, 1, 3, 7, 15 and 30 days. 
The blood samples were collected in centrifugation tube 
and add heparin (0.2 ml for 1.0 ml blood) as an 
anticoagulant. The plasma was obtained by centrifuging 
the blood samples at 3000 rpm for 10 mins, decanting 
supernatant fluid into the clean, dry test tube. 10l of the 
plasma was collected and the blood glucose level was 
estimated by GOD/POD method. 
D. Estimation of Biochemical parameters
9, 11
: 
Fasting Blood Plasma Glucose Estimation: 
Blood plasma glucose was estimated by the GOD/POD 
(Glucose oxidase and peroxidase) method using the 
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GLUCOSE–GOD/POD kit (GSK Qualisystems; 
AR106). 
GOD /POD method 
The older methods were based on the reducing property 
of glucose. But these methods do not measure the true 
glucose because of interferences. Subsequently other 
chemical and enzymatic methods were developed to 
overcome this problem. The GOD/POD method is one 
such evolved method by Trinder in 1964. This method is 
precise, simple, and single stepped, rapid, safe and 
reliable. Hence, in the present study, we have adopted 
this method. Trinder’s method (1964) utilizes two 
enzymes Glucose oxidase (GOD) and peroxidase (POD) 
along with the chromogen 4- amino antipyrine and 
phenol. This method is intended for in-vitro quantitative 
determination of glucose in serum/plasma and CSF. 
There was no interference due to the substances like 
creatinine, fructose, galactose, reduced glutathione, 
ascorbic acid and xylose. Hemoglobin or bilirubin up to 
10mg% does not affect the test. 
Principle 
Glucose is oxidized by the enzyme Glucose oxidase 
(GOD) to give D-gluconic acid and hydrogen peroxide. 
Glucose present in the blood is oxidized by the enzyme 
Glucose oxidase (GOD) to give D-gluconic acid and 
hydrogen peroxide. Hydrogen peroxide further reacts 
with 4-aminoantipyrine and phenol in presence of the 
enzyme peroxidase (POD) to undergo oxidation to 
produce a red colour quinoneimine dye. 
The intensity of the colour produced is directly 
proportional to glucose concentration in the sample. 
GOD 
                                          
POD 
                                 
                     
Preparation of working reagent  
1 vial of enzyme powder was transferred to 1 bottle 
(100ml) of buffer solution and mixed gently to dissolve 
which is ready to use. 
Reagent storage and stability 
 All the reagents were stored at 2-8C, which is 
stable till the expiry date, reagents were not freeze. 
 Capped reconstituted reagents are stable for 30 days 
at 2-8C. 
 Reconstituted enzyme reagents when stored at 2-
8C develops a slight pink colour, however this 
does not affect the performance of the enzyme 
reagent. 
 The reagents should not be used if caking is 
observed due to possible moisture penetration. 
Procedure 
Pipette out the solutions into clean, dry test tubes and 
labelled as blank (B), Standard (S), and test (T).Distilled 
water was considered as blank solution. To 1.0 ml of the 
reagent, 10 µl of standard glucose (100 mg/ dl) was 
added and incubated for 15 min at 370º C. This 
incubated mixture was aspirated and concentration of 
standard was calibrated to show a value of 100 mg/ dl. 
This process is duplicated to confirm the calibration 
value and was considered as correct if the value was 
within 5 % of the original value. 
The fasting blood plasma glucose was estimated by 
adding 10 µl of the plasma sample to 1.0 ml of the 
reagent, mixed well and incubated at 37
0
 C for 15 min. 
This incubated mixture was aspirated and absorbance 
recorded against a reagent blank at 510 nm using 
Photometer (GSK Qualisystems; AR106).  
 
Table 1: General Procedure of GOD/POD for the estimation of glucose in plasma 
S. No Content Blank Standard Test 
1 Working reagent enzyme 1.0 ml 1.0 ml 1.0 ml 
2 Distilled water 10 l 10 l 10 l 
3 Standard glucose - 10 l - 
4 Serum (sample) - - 10 l 
 
Calculation:  
The glucose concentrat ion in mg % was 
calcula ted us ing the formula.   
Concentration of Sample (mg/ dl) = 
                    
                      
× 100 
 
 
 
E. Statistical Analysis: 
The values are expressed as mean ± SEM. The data was 
analysed by using student’s t-test using one way analysis 
of variance (ANOVA) followed by Dunnett multiple 
component test. Statistical significance was set at P < 
0.05. 
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RESULT AND DISCUSSION 
Fasting Blood Plasma Glucose: X 
The fasting blood plasma glucose of the different groups 
of normal animals during the period of study is 
presented in graph 2, which shows that the mean (± 
SEM) fasting plasma glucose values of the normal 
control group of mice was 96.4±1.364 
mg/dl,104.2±1.497 mg/dl, 102±1.342 mg/dl, 97.4±1.470 
mg/dl, 99.8±1.625 mg/dl, 91.6±1.503 mg/dl,100.6±0.95 
mg/dl and98.0±1.125 mg/dl on day 0, ½, 1, 2, 4, 8, 12 
and 24h respectively. The above values show that the 
fasting plasma glucose in the normal group of mice was 
maintained within the normal range throughout the 
period of study. 
The Glibenclamide (600 μg/kg) treated normal mice 
show a mean (±SEM) fasting plasma glucose of 
104.2±2.835 mg/dl on the 0 h which was reduced to 
88.0±2.302 mg/dl on ½ h, 85.6±2.713 mg/dl on 1 h, 
82.4±2.441 mg/dl on 2 h, 77.8±2.782 mg/dl on 4 h, 
72.4±2.542 mg/dl on 8 h, 75.16±2.212 mg/dl on 12 h 
and 86.83±3.554 mg/dl on 24 h. These changes in 
fasting plasma glucose values illustrate that the normal 
mice treated with Glibenclamide show a progressive and 
significant (p<0.01) reduction in fasting plasma glucose, 
during the 24h on single dose treatment period in 
comparison to the normal group of mice. This indicates 
that the Glibenclamide treatment of normal mice is able 
to reduce the fasting plasma glucose levels below the 
normal up to 8 h but it further increase on 12 h and 24 h 
of the study period.  
The herbal preparation-1 (1.0 ml/kg) treated normal 
mice show a mean (±SEM) fasting plasma glucose of 
100.8±1.114 mg/dl on the 0 h which was reduced to 
97.2±1.319 mg/dl on ½ h, 93.2±1.114 mg/dl on 1 h, 
90.4±1.166 mg/dl on 2 h, 87.0±1.265 mg/dl on 4 h, 
81.0±1.342 mg/dl on 8 h, 83.83±1.108 mg/dl on 12 h 
and 86.33±1.687 on 24 h. These changes in fasting 
plasma glucose values illustrate that the normal mice 
treated with PH-1 show a progressive and significant 
(p<0.01) reduction in fasting plasma glucose, during the 
24h on single dose treatment period in comparison to the 
normal group of mice. This indicates that the PH-1 
treatment of normal mice is able to reduce the fasting 
plasma glucose levels below the normal up to 8 h but it 
further increase on 12 h and 24 h of the study period. 
The PH-1 (2.0 ml/kg) treated normal mice show a mean 
(±SEM) fasting plasma glucose of 99.6±1.369 mg/dl on 
the 0 h which was increased to 100.2±0.8602 mg/dl on 
½ h, and later reduced to88.2±1.562 mg/dl on 1 h, 
81.4±1.860 mg/dl on 2 h, 75.6±2.561 mg/dl on 4 h, 
69.4±2.441 mg/dl on 8 h, 88.0±1.581 mg/dl on 12 h and 
91.8±0.7348 mg/dl on 24 h. These changes in fasting 
plasma glucose values illustrate that the normal mice 
treated with PH-1 show a progressive and significant 
(p<0.01) reduction in fasting plasma glucose, during the 
24h on single dose treatment period in comparison to the 
normal group of mice. This indicates that the PH-1 
treatment of normal mice is able to reduce the fasting 
plasma glucose levels below the normal up to 8 h but it 
further increase on 12 h and 24 h of the study period. 
The fasting plasma glucose of the different groups of 
diabetic animals during the period of study is given in 
table No 7 and presented in graph 3, which shows that 
the mean fasting plasma glucose (± SEM) in the diabetic 
control group of mice was found to be 270.6±3.140 
mg/dl, 270.6±3.140 mg/dl, 270.6±3.140 mg/dl, 
266.8±2.905 mg/dl, 269.2±2.653 mg/dl and 261.4±5.683 
mg/dl on day 0, day 1, day 3, day 7, day15 and day 30 
respectively. These elevated fasting plasma glucose 
levels were found to have been maintained throughout 
the 30 days of treatment period indicating that the mice 
are rendered diabetic.  
The Glibenclamide (600 µg/kg) treated diabetic mice 
show a mean (± SEM) fasting plasma glucose of 
289.4±1.691 mg/dl on day 0, 269.8±3.497 mg/dl on 1 
day, 227.0±1.378 mg/dl on 3 day, 212.8±1.020 mg/dl on 
7 day which was reduced to 178.0±1.000 mg/dl on day 
15 which reduced further to132.6±1.691 mg/dl on day 
30. These changes in fasting plasma glucose values 
illustrate that the diabetic mice treated with 
Glibenclamide show a progressive and significant 
(p<0.01) reduction in fasting plasma glucose, during the 
four weeks of treatment period in comparison to the 
diabetic group of mice. This indicates that the 
Glibenclamide treatment of diabetic mice is able to bring 
back the fasting plasma glucose levels nearer to normal 
range in the four weeks of study period. 
The PH-1 (1.0 ml/ kg) treated diabetic mice show mean 
(± SEM) fasting plasma glucose of 272.2±2.223 mg/dl 
on day 0, 267.2±2.223 mg/dl on 1 day, 256.8±2.154 
mg/dl on 3 day, 238.8±2.059 mg/dl on 7 day which was 
found to have been reduced 212.4±1.661 mg/dl on day 
15 and 202.2±1.655 mg/dl on day 30. These changes in 
fasting plasma glucose values illustrate that the diabetic 
mice treated with PH-1 (1.0 ml/kg) show a progressive 
and significant (p<0.01) reduction in fasting plasma 
glucose during the 30 days of treatment period in 
comparison to the diabetic group of mice.  
The PH-1 (2.0 ml/kg) treated diabetic mice shows mean 
(± SEM) fasting plasma glucose of 279.4±3.696 mg/dl 
on day 0, 269.2±3.652 mg/dl on day 1, 247.4±3.076 
mg/dl on day 3, 221.2±2.577 mg/dl on day 7 which was 
reduced to 199.6±2.943 mg/dl on day 15 which reduced 
further to 180.4±2.619 mg/dl on day 30. These changes 
in fasting plasma glucose illustrate that the diabetic mice 
treated with PH-1 (2.0 ml/kg) show a progressive and 
significant (p<0.01) reduction in fasting plasma glucose 
during the 30 days of treatment period in comparison to 
diabetic group of mice. The above observations show 
that the treatment of diabetic mice with PH-1 reduces the 
fasting plasma glucose of diabetic mice at all the tested 
dose levels, but the high dose of PH-1 (i.e. 2.0 ml/kg of 
PH-1) was able to reduce fasting plasma glucose which 
was comparable with the reduction caused by 
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Glibenclamide treatment during the 30 days of 
treatment.     
The PH-2 (1.0 ml/kg) treated diabetic mice shows mean 
(± SEM) fasting plasma glucose of 274.2±3.625 mg/dl 
on day 0, 267.0±3.271 mg/dl on 1 day, 224.0±3.317 
mg/dl on 3 day, 205.0±2.608 mg/dl on 7 day which was 
reduced to 180.6±1.913 mg/dl on day 15 which reduced 
further to117.6±1.887 mg/dl on day 30. These changes 
in fasting serum glucose illustrate that the diabetic mice 
treated with PH-2 (1.0 ml/kg) show a progressive and 
significant (p<0.01) reduction in fasting plasma glucose 
during the 30 days of treatment period in comparison to 
diabetic group of mice.  
The PH-2 (2.0 ml/kg) treated diabetic mice shows mean 
(± SEM) fasting plasma glucose of 277.0±3.536 mg/dl 
on day 0, 260.8±1.744 mg/dl on 1 day, 217.6±1.208 
mg/dl on 3 day, 182.8±1.393 mg/dl on 7 day which was 
found to have been reduced 161.4±1.990 mg/dl on day 
15 and 137.2±2.775 mg/dl on day 30. These changes in 
fasting plasma glucose illustrate that the diabetic mice 
treated with PH-2 (2.0 ml/kg) show a progressive and 
significant (p<0.01) reduction in fasting plasma glucose 
during the 30 days of treatment period in comparison to 
diabetic group of mice. The above observations show 
that the treatment of diabetic mice with PH-2 reduces the 
fasting plasma glucose of diabetic mice at all the tested 
dose levels, but the high dose of PH-1 (i.e. 2.0 ml/kg of 
PH-2) was able to reduce fasting plasma glucose which 
was comparable with the reduction caused by 
Glibenclamide treatment during the 30 days of 
treatment.   
The PH-3 (1.0 ml/ kg) treated diabetic mice show mean 
(± SEM) fasting plasma glucose of 272.0±3.406 mg/dl 
on day 0, 257.0±3.114 mg/dl on 1 day, 216.8±2.888 
mg/dl on 3 day, 211.4±2.337 mg/dl on 7 day which was 
found to have been reduced 178.6±2.522 mg/dl on day 
15 and 137.0±2.775 mg/dl on day 30. These changes in 
fasting plasma glucose values illustrate that the diabetic 
mice treated with PH-3 (1.0 ml/kg) show a progressive 
and significant (p<0.01) reduction in fasting plasma 
glucose during the 30 days of treatment period in 
comparison to the diabetic group of mice.  
The PH-3 (2.0 ml/kg) treated diabetic mice shows mean 
(± SEM) fasting plasma glucose of 271.6±4.13 mg/dl on 
day 0, 253.8±3.813 mg/dl on 1 day, 202.0±3.27 mg/dl 
on 3 day, 175.8±2.615 mg/dl on 7 day which was found 
to have been reduced 158.4±2.839 mg/dl on day 15 and 
132.6±1.806 mg/dl on day 30. These changes in fasting 
plasma glucose illustrate that the diabetic mice treated 
with PH-3 (2.0 ml/kg) show a progressive and 
significant (p<0.01) reduction in fasting plasma glucose 
during the 30 days of treatment period in comparison to 
diabetic group of mice. The above observations show 
that the treatment of diabetic mice with PH-3 reduces the 
fasting plasma glucose of diabetic mice at all the tested 
dose levels, but the high dose of PH-3 (i.e. 2.0 ml/kg of 
PH-1) was able to reduce fasting plasma glucose which 
was comparable with the reduction caused by 
Glibenclamide treatment during the 30 days of 
treatment. 
 
Graph 1: Effect of PH-1 (1 ml/kg) on fasting blood plasma glucose levels after oral administration in normal mice 
 
 
Graph 2: Effect of PH-1 (2 ml/kg) on fasting blood plasma glucose levels after oral administration in normal mice 
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Graph 3: Effect of PH-1 on fasting blood plasma glucose levels after oral administration in alloxan-induced mice 
 
 
Graph 4: Effect of PH-2 on fasting blood plasma glucose levels after oral administration in alloxan-induced mice 
 
 
Graph 5: Effect of PH-3 on fasting blood plasma glucose levels after oral administration in alloxan-induced mice 
 
DISCUSSION 
Diabetes mellitus is possibly the world’s largest growing 
metabolic disease, and the knowledge on the 
heterogeneity of this order is advanced, the need for 
more appropriate therapy increases. Traditional plant 
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diabetic complications as an alternative for conventional 
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help as "potentiators" for these drugs or play a 
supportive role in regulating the dosage of 
hypoglycaemics and maintain the quality of the diabetic 
life. 
In the indigenous Indian system of medicine (Ayurveda) 
a mention was made on good number of plants for the 
cure of diabetes but  the bioreactivity of single plant 
preparation is disappointing and most of these remedies 
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have moderate potency as well as toxicity thus are not 
fast acting nor overtly dangerous where as in the 
Polyherbal preparation forms they are likely to contain 
several bioreactive components which can act together 
and elicit additive or synergistic effects which shows 
optimal therapeutics response that are not apparent when 
the bioreactive compounds are used independently. 
Various herbal formulations such as diamed, coagent db, 
hyponidd, and SMK001 are reported in literature as an 
antidiabetic formulation while we have made an attempt 
to use three different plants products in our study viz. 
wheat germ oil, fresh juice of Coriandrum sativum and 
Aloe vera to prepare Polyherbal preparation. 
In the present study we have found that Glibenclamide 
(600µg/kg) treated normal group of mice showed 
significant (P<0.001) and progressive reduction in 
fasting plasma glucose levels during the period of study 
when compared with the normal untreated. We have 
also observed that PH-1 treated normal group of mice 
produce a progressive and significant reduction in 
fasting plasma glucose level during the period of study 
when compared with normal untreated mice at all the 
selected dose levels i.e. at 1.0ml/kg and 2.0ml/kg but the 
higher dose (2.0ml/kg) have shown more constituent 
results throughout the study period. 
In the study the group of diabetic mice showed elevated 
fasting plasma glucose levels. This observation suggests 
that single i.p infection of alloxan (150mg/kg) produced 
a reproducible and consistent diabetes mellitus and 
appears to be a suitable model of diabetes in our 
laboratory conditions.  
The Glibenclamide (600µg/kg) treated diabetic group of 
mice showed significant (P<0.001) and progressive 
reduction in fasting plasma glucose levels during the 30 
days of study period when compared with the diabetic 
group of mice. In agreement with the present results, 
several studies have shown anti-diabetic activity upon 
Glibenclamide treatment. The PH-1, 2 and 3 treated 
groups of mice shown progressive and significant 
(P<0.001) reduction in fasting plasma glucose of 
diabetic mice when compared with untreated diabetic 
mice at all selected dose levels (1.0 ml/kg and 2.0ml/kg) 
but the higher dose 2.0 ml/kg have shown more 
consistent results through the 30 days period of study.  
In the present study it can be postulated that PH-1 
significantly reduce the normal blood glucose level and 
PH-1, 2and 3 significantly reduce the elevated blood 
glucose level in diabetic mice. This indicated possible 
antidiabetic effect of Polyherbal preparation.  
Experimental diabetes is suggested to result from 
Alloxan, a β-cytotoxin, a broad spectrum antibiotic has 
been widely used for inducing the diabetes mellitus in 
variety of animals. Following its administration, alloxan 
is concentrated in the islets it is reduced to dialuric acid. 
This acid is unstable in aqueous solutions and undergoes 
oxidation back to alloxan, accompanied by generation of 
O2
-
, hydrogen peroxide and hydroxyl radicals by Fenton 
type reaction
137
 the islet cells have low concentrations of  
super oxide dismutase (SOD), catalase and glutathione 
peroxidase it causes a massive destruction of β-cells of 
islets of langerhans by accumulation of cytotoxic free 
radicals resulting in reduced synthesis and release of 
insulin which paves the ways for the decreased 
utilization of glucose by the tissues and induce 
experimental diabetes mellitus. It is well established that 
sulphonylureas produce hypoglycemia by increasing the 
secretion of insulin from pancreas and these compounds 
are active in mild alloxan-induced diabetes whereas they 
are inactive in intense alloxan diabetes (nearly all β-cells 
have been destroyed). Since our results showed that 
Glibenclamide reduced blood glucose levels in 
hyperglycemic animals, the state of diabetes is not 
severe. Alloxan-treated animals receiving the herbal 
preparation showed reduction of blood glucose levels in 
comparison to control and this could be due to the 
possibility that some β-cells are still surviving to act 
upon by herbal preparation to exert its insulin releasing 
effect. Moreover, like sulphonylureas oral 
administration of herbal preparation produced 
hypoglycemia in normal animals. This suggests that the 
mode of action of the active ingredients of herbal 
preparation is probably mediated by an enhanced 
secretion of insulin, like sulphonylureas.   
The possibility of antidiabetic effect of herbal 
preparation may be due to the effect of active 
constituents of different plants, viz, vitamins such vit  C, 
minerals such as chromium, manganese, magnesium, 
zinc and hydro-soluble fiber glucomannan from Aloe 
vera, vitamin E (tocophherols) from wheat germ oil, and 
vitamin such as vit A from Coriandrum sativum. 
Ascorbic acid is a reducing agent and can reduce in cells 
by reaction with glutathione, which can be catalyzed by 
protein disulfide isomerase and glutaredoxins and 
thereby neutralize reactive oxygen species such as 
hydrogen peroxide which is known to mediate the 
glycation-dependent degradation of several proteins and 
is widely involved in the damage of various β-cells and 
decreasing the β-cell mass in type-2 diabetes however, it 
can also reduce metal ions which leads to the generation 
of free radicals through the Fenton reaction. 
 
2 Fe3+ + Ascorbate → 2 Fe2+ + Dehydroascorbate 
2 Fe2+ + 2 H2O2 → 2 Fe3+ + 2 OH· + 2 OH− 
Magnesium is co-factor in glucose oxidation, modulates 
glucose transport across cell membranes. May increase 
insulin secretion and/or improve insulin 
sensitivity/peripheral glucose uptake where as 
glucomannan (hydrosoluble fiber) delaying glucose 
absorption. 
Manganese, zinc and iron are co-factor for superoxide 
dismutase (SODs) that catalyse the breakdown of the 
superoxide anion into oxygen and hydrogen peroxide 
which further reduce to give water and protect β-cells 
from the toxic effects of reactive oxygen species. 
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Vitamin E is lipophilic and inhibits lipid 
peroxidationwhich occurs in the plasma membrane and 
damage membrane structure and permeability, 
scavenging lipid peroxyl radicals to yield lipid peroxides 
and the tocophroxyl radicals and protects membrane 
from oxidation. In other words inhibition of lipid 
peroxidation by antioxidants vit E improves β-cells 
function which might influence protein glycation, lipid 
oxidation, and insulin secretion/sensitivity. It may also 
affect nonoxidative glucose metabolism. Besides these 
active chemical constituents of different plants 
Polyherbal preparation also possesses vit A, vit B12, 
digestive enzymes such as amylase and lipase that can 
offset the toll blood glucose level. 
Therefore, Polyherbal preparation is potent in preserving 
β-cell function in diabetes by scavenging free radicals 
liberated by alloxan in diabetic rats and also regulate 
key reactions involves in turn on and turn off insulin 
action as well as in glucose utilization. On the basis of 
above results, it could be concluded that Polyherbal 
preparation, a combination of three herbal plants exert a 
significant antidiabetic effect. This could be due to 
different types of active principles, each with a single or 
a diverse range of biological activities, which serves as a 
good adjuvant in the present armamentarium of 
antidiabetic drug.  
CONCLUSION 
The present study on the PH-1, 2 and 3 formulated from 
three different plants i.e. Wheat germ oil, fresh juice of 
Coriandrum sativum and Aloe vera gel in three different 
ratio’s were started with an expectation and objective to 
explore the possibility of the drug to exert antidiabetic 
effect. In this study, alloxan induced diabetic animals 
were used. Antidiabetic animals were treated with 
different doses of PH-1, 2 and 3 to assess the effect of 
the drugs. After treatment, to analyze the effect of the 
drug glucose estimation test was performed. The data 
obtained were satisfactory and conclusive so as and to 
accomplish our objectives. In conclusion, the present 
data indicated that the PH-1 i.e. Wheat germ oil, fresh 
juice of Coriandrum sativum and Aloe vera in the ratio 
of 1:1:1 showed significant glucose lowering effect in 
normal mice and PH-1, 2 i.e. Wheat germ oil, fresh juice 
of Coriandrum sativum and Aloe vera in the ratio of 
2:2:1 and PH-3 i.e. Wheat germ oil, fresh juice of 
Coriandrum sativum and Aloe vera in the ratio of 1:2:2 
showed significant glucose lowering effect in alloxan 
induced diabetic mice. This study suggests that PH-1, 2, 
and 3 posses antidiabetic activity and is going to be a 
promising antidiabetic preparation for masses. Exact 
mechanism underlying this effect is not clear, but 
apparently may be due to preserving β-cell function in 
diabetic mice. Further studies are needed to elucidate the 
mechanism of action and to know the active principle/s 
involved in producing the effect. Keeping in view the 
tremendous pharmacological activities this herbal 
preparation possess, it may be utilized to alleviate the 
symptoms of diabetes, however it has to be confirmed 
by clinical trials before put into the therapy.  
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